Oxford Immunotec Global PLC (NASDAQ: OXFD) and Quidel Corporation (NASDAQ:QDEL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitabiliy.

Valuation and Earnings

This table compares Oxford Immunotec Global PLC and Quidel Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Oxford Immunotec Global PLC $90.47 million 3.68 -$22.95 million ($1.05) -13.85
Quidel Corporation $214.97 million 3.98 $39.80 million $0.10 257.43

Quidel Corporation has higher revenue and earnings than Oxford Immunotec Global PLC. Oxford Immunotec Global PLC is trading at a lower price-to-earnings ratio than Quidel Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Oxford Immunotec Global PLC and Quidel Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oxford Immunotec Global PLC -25.83% -31.48% -22.01%
Quidel Corporation 1.83% 1.94% 1.02%

Analyst Recommendations

This is a summary of recent ratings for Oxford Immunotec Global PLC and Quidel Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Immunotec Global PLC 0 0 2 0 3.00
Quidel Corporation 0 3 2 0 2.40

Oxford Immunotec Global PLC presently has a consensus target price of $19.00, suggesting a potential upside of 30.67%. Quidel Corporation has a consensus target price of $23.88, suggesting a potential downside of 7.25%. Given Oxford Immunotec Global PLC’s stronger consensus rating and higher probable upside, research analysts plainly believe Oxford Immunotec Global PLC is more favorable than Quidel Corporation.

Risk & Volatility

Oxford Immunotec Global PLC has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Quidel Corporation has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Institutional & Insider Ownership

87.6% of Oxford Immunotec Global PLC shares are owned by institutional investors. Comparatively, 89.6% of Quidel Corporation shares are owned by institutional investors. 7.6% of Oxford Immunotec Global PLC shares are owned by company insiders. Comparatively, 22.0% of Quidel Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Quidel Corporation beats Oxford Immunotec Global PLC on 10 of the 12 factors compared between the two stocks.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.